These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 39011717

  • 1. [Renoprotective treatments : renin-angiotensin-aldosterone system blockade and beyond].
    Esnault V.
    Rev Prat; 2024 Jun; 74(6):s19-s22. PubMed ID: 39011717
    [Abstract] [Full Text] [Related]

  • 2. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV, Nagaraju SP, Bhojaraja MV, Prabhu RA, Rangaswamy D, Rao IR.
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [Abstract] [Full Text] [Related]

  • 3. Renalism with Renin Angiotensin Aldosterone System Blockade: What Is the Consensus in Advanced Chronic Kidney Disease?
    Turino Miranda K, Ahmed SB.
    Can J Cardiol; 2024 Sep; 40(9):1729-1731. PubMed ID: 38777038
    [No Abstract] [Full Text] [Related]

  • 4. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S, García CO, Rodríguez E, Barrios C, Otero S, Mojal S, Pascual J, Soler MJ.
    Nefrologia (Engl Ed); 2018 Sep; 38(2):197-206. PubMed ID: 29102270
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A, Montecucco F.
    Curr Pharm Des; 2012 Sep; 18(7):950-1. PubMed ID: 22283769
    [No Abstract] [Full Text] [Related]

  • 6. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH, Luft FC.
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [Abstract] [Full Text] [Related]

  • 7. Slowing Progression in CKD: DAPA CKD and Beyond.
    Larmour K, Levin A.
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
    [No Abstract] [Full Text] [Related]

  • 8. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
    Lattanzio MR, Weir MR.
    Curr Hypertens Rep; 2010 Oct; 12(5):369-77. PubMed ID: 20703958
    [Abstract] [Full Text] [Related]

  • 9. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 10. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC, Cherney D, Gee PO, Harris RC, Kliger AS, Tuttle KR, Quaggin SE, DKD-Collaborative ASN Taskforce.
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [Abstract] [Full Text] [Related]

  • 11. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K, Smith H, Biederman J.
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [Abstract] [Full Text] [Related]

  • 12. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G, Ruilope LM.
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC, Wu YT, Yang WC, Tsai MJ, Liu JS, Yang CY, Li SY, Ou SM, Tarng DC, Hsu CC.
    PLoS One; 2017 Apr; 12(12):e0189126. PubMed ID: 29216260
    [Abstract] [Full Text] [Related]

  • 14. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 15. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ.
    Circ Heart Fail; 2014 May 09; 7(3):536. PubMed ID: 24847129
    [No Abstract] [Full Text] [Related]

  • 16. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
    Rutkowski B, Tylicki L.
    J Ren Nutr; 2015 Mar 09; 25(2):194-200. PubMed ID: 25576239
    [Abstract] [Full Text] [Related]

  • 17. An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
    Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J.
    Expert Opin Pharmacother; 2015 Mar 09; 16(15):2283-92. PubMed ID: 26389772
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S, LeFevre J, Olstinske K, Ravindran S, Munusamy S.
    Adv Biol (Weinh); 2024 Mar 09; 8(3):e2300496. PubMed ID: 38065929
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ.
    Contrib Nephrol; 2013 Mar 09; 179():7-14. PubMed ID: 23652444
    [Abstract] [Full Text] [Related]

  • 20. Aldosterone blockade in chronic kidney disease.
    Hirsch JS, Drexler Y, Bomback AS.
    Semin Nephrol; 2014 May 09; 34(3):307-22. PubMed ID: 25016401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.